Visual Prognosis in Patients with Behçet’s Disease Receiving Colchicine, Systemic Corticosteroid or Cyclosporin

Abstract

We reviewed retrospectively the charts of 36 patients (72 eyes) with BehÇet’s disease. The visual acuities in 21 patients receiving colchicine (group A) gradually decreased with time. The visual acuities in 9 patients receiving colchicine and systemic corticosteroid (group B) gradually decreased after the onset of the disease and were significantly worse than those in group A 10 and 15 years after onset. The visual acuities in 6 patients receiving colchicine and cyclosporin (group C) gradually decreased, and their visual acuity scores were similar to those in group A.

Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease

“…Among the 15 open studies with ciclosporin A in eye disease, all supporting its efficacy, 13 also provided data on safety (table 3). 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Ciclosporin dose was between 2–10 mg/kg/day and the mean (SD) duration of treatment was 19.1 (16.2) months in these studies.…”

Update on the therapy of Behçet disease

“…Azathioprine Eye involvement RCT [Yazici et al 1990] Retrospective study [Saadoun et al 2010] Vascular disease RCT [Yazici et al 1990] GI involvement Retrospective study Neuro-Behçet Case series [Kurtuncu et al 2008] Mycophenolate mofetil Neuro-Behçet Case series [Shugaiv et al 2011] Cyclosporine A Eye involvement RCTs [Ozyazgan et al 1992;Masuda et al 1989;BenEzra et al 1988] Open-label studies [Ermakova, 2003;Ozdal et al 2002;Fujino et al 1999;Sullu et al 1998;Whitcup et al 1994;Sajjadi et al 1994;Pacor et al 1994;Hayasaka et al 1994;Atmaca and Batioglu, 1994;Chavis et al 1992; [Mochizuki et al 1991[Mochizuki et al , 1992Ishioka et al 1994] Cyclophosphamide Vascular disease Retrospective studies [Hamuryudan et al 1994[Hamuryudan et al , 2004 Neuro-Behçet Retrospective study...…”

Colchicine in the treatment of the inflammatory phase of Graves' ophthalmopathy: a prospective and randomized trial with prednisone

“…Colchicine is an alkaloid that has been used for an increasing number of diseases due to its anti-inflammatory effects (4)(5) ; it reduces motility, chemo-Purpose: To investigate if colchicine is valuable in the treatment of Graves' ophthalmopathy (GO), we compared its effect with prednisone in 22 patients during the inflammatory phase of GO. Methods: All patients, similar in age, sex and smoking habits, were euthyroid for at least 3 months and randomly divided into two groups, one treated with colchicine (1.5 mg/day) and the other treated with prednisone (0.75 mg/ kg/day).…”